Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
31,640,175
-
Shares change
-
-366,670
-
Total reported value, excl. options
-
$1,176,015,102
-
Value change
-
-$28,756,691
-
Put/Call ratio
-
66.43%
-
Number of buys
-
63
-
Number of sells
-
-87
-
Price
-
$37.17
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2020
216 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2020.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31,640,175 shares
of 207,440,936 outstanding shares and own 15.25% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5,465,715 shares), Meditor Group Ltd (2,679,835 shares), WASATCH ADVISORS INC (2,409,683 shares), VANGUARD GROUP INC (2,304,347 shares), Pentwater Capital Management LP (2,169,022 shares), BlackRock Inc. (2,025,704 shares), STATE STREET CORP (1,802,750 shares), MARSHALL WACE, LLP (1,366,105 shares), CREDIT SUISSE AG/ (995,396 shares), and BOXER CAPITAL, LLC (975,000 shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.